Living with fibromatosis, often referred to as desmoid tumors, can be a source of significant anxiety. Although these growths are technically benign and do not spread like cancer, they can be locally aggressive, invading nearby muscles and causing pain or restricted movement. The unpredictability of the condition where some tumors grow rapidly while others stabilize on their own, disrupts daily life and creates uncertainty about the future. Treatment is essential to control the tumor’s size, preserve limb function, and manage pain. 

Because these tumors are rare and behave differently in every patient, there is no single standard of care. Some individuals may only require careful monitoring, a strategy known as active surveillance, while others with symptomatic tumors need medical intervention. The choice of treatment depends heavily on the tumor’s location, growth rate, and impact on daily activities (Desmoid Tumor Research Foundation, 2023). 

Overview of treatment options for Fibromatosis 

The approach to treating fibromatosis has shifted significantly away from surgery, which often leads to high recurrence rates. Instead, the current standard emphasizes medical management to stop growth or shrink the mass. 

Treatment typically follows a stepped approach, starting with milder therapies and progressing to stronger medications only if necessary. The primary goals are to alleviate pain and halt tumor progression without causing unnecessary harm. Systemic medications, ranging from anti-inflammatories to advanced targeted therapies, are the cornerstone of this strategy. 

Medications used for Fibromatosis 

Doctors use a variety of drug classes to manage fibromatosis, often utilizing medications originally developed for other conditions. 

Nonsteroidal anti-inflammatory drugs (NSAIDs): Sulindac or meloxicam are frequently the first line of defense for slow-growing or smaller tumors. While best known as pain relievers, clinical experience suggests they may also help stabilize tumor growth in mild cases. 

Hormone therapy: Because some desmoid tumors appear to be influenced by estrogen, doctors may prescribe anti-estrogen medications like tamoxifen. This is often used alone or in combination with NSAIDs and is generally considered a gentle option compared to chemotherapy. 

Chemotherapy: This is reserved for tumors that are growing rapidly or threatening vital organs. Regimens can vary from low-dose combinations to traditional agents like doxorubicin. These drugs are potent and usually administered intravenously when immediate tumor shrinkage is critical. 

Targeted therapies: Drugs like sorafenib or the recently approved nirogacestat represent the newest advancement. These oral medications target specific enzymes or pathways involved in tumor growth and offer a powerful alternative for patients whose tumors have not responded to other treatments. 

How these medications work 

The medications used for fibromatosis target the cellular signals that tell the tumor to grow. 

NSAIDs work by inhibiting enzymes that produce inflammation-promoting chemicals. By reducing these chemicals, the medication creates a less favorable environment for the tumor to expand. Hormone therapies function by blocking estrogen receptors on the tumor cells, essentially cutting off a potential growth signal. 

Targeted therapies work on a more specific level by interfering with internal communication pathways, such as the Notch signaling pathway. These pathways act like switches stuck in the “on” position, driving the tumor cells to multiply. Targeted drugs turn these switches off, halting progression. 

Side effects and safety considerations 

Side effects vary widely depending on the intensity of the treatment. NSAIDs can cause stomach irritation or kidney strain if taken long-term. Hormone therapies like tamoxifen may cause menopausal symptoms, such as hot flashes, or increase the risk of blood clots. 

Targeted therapies and chemotherapy carry more significant risks. Tyrosine kinase inhibitors can cause fatigue, high blood pressure, or skin rashes. Chemotherapy often leads to hair loss and an increased risk of infection. Patients should seek immediate medical care if they experience severe abdominal pain or signs of a blood clot, such as leg swelling. 

Since everyone’s experience with the condition and its treatments can vary, working closely with a qualified healthcare provider helps ensure safe and effective care. 

References 

  1. Desmoid Tumor Research Foundation. https://dtrf.org 
  1. National Organization for Rare Disorders. https://rarediseases.org 
  1. American Cancer Society. https://www.cancer.org 
  1. National Cancer Institute. https://www.cancer.gov 

Medications for Fibromatosis

These are drugs that have been approved by the US Food and Drug Administration (FDA), meaning they have been determined to be safe and effective for use in Fibromatosis.

Found 2 Approved Drugs for Fibromatosis

Xiaflex

Generic Name
Histolyticum

Xiaflex

Generic Name
Histolyticum
XIAFLEX is indicated for the treatment of adult patients with Dupuytren’s contracture with a palpable cord. XIAFLEX is indicated for the treatment of adult men with Peyronie’s disease with a palpable plaque and curvature deformity of at least 30 degrees at the start of therapy. XIAFLEX is a combination of bacterial collagenases indicated for: The treatment of adult patients with Dupuytren’s contracture with a palpable cord ( 1 ) The treatment of adult men with Peyronie’s disease with a palpable plaque and curvature deformity of at least 30 degrees at the start of therapy ( 1 )

Ogsiveo

Generic Name
Nirogacestat

Ogsiveo

Generic Name
Nirogacestat
OGSIVEO is indicated for adult patients with progressing desmoid tumors who require systemic treatment. OGSIVEO is a gamma secretase inhibitor indicated for adult patients with progressing desmoid tumors who require systemic treatment. ( 1 )
Showing 1-2 of 2
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances